Price
$0.9223
Decreased by -3.93%
Dollar Volume
65.68 K
ADR%
9.62
Earnings Report Date (estimate)
Nov 2, 22 (N/A)
Market Cap.
36.64 M
Shares Float
20.82 M
Shares Outstanding
39.72 M
Beta
1.97
Price / Earnings
-0.28
BPR
3.78
20D Range
0.86 1.12
50D Range
0.86 1.16
200D Range
0.86 2.98
  • Quarterly Earnings
  • Annual Earnings
Reported Date EPSChange YoY EstimateSurprise
Nov 2, 22 -0.44
Increased by +43.59%
-0.58
Increased by +24.14%
Aug 4, 22 -0.47
Increased by +40.51%
-0.67
Increased by +29.85%
May 4, 22 -0.84
Decreased by -13.51%
-0.73
Decreased by -15.07%
Mar 10, 22 -0.89
Increased by +18.35%
-0.83
Decreased by -7.23%
Nov 4, 21 -0.78
Increased by +92.91%
-0.81
Increased by +3.70%
Aug 5, 21 -0.79 -0.81
Increased by +2.47%
May 10, 21 -0.74 -0.90
Increased by +17.78%
Mar 23, 21 -1.09 -0.82
Decreased by -32.93%
  • Quarterly Financials
  • Annual Financials
Fiscal ending date RevenueChange YoY IncomeChange YoY ProfitChange YoY
Sep 30, 22 4.11 M
Increased by +167.14%
-18.62 M
Increased by +43.78%
Decreased by -453.51%
Increased by +78.96%
Jun 30, 22 3.69 M
Increased by +139.03%
-19.92 M
Increased by +33.18%
Decreased by -539.51%
Increased by +72.05%
Mar 31, 22 2.57 M
Increased by +182.53%
-35.62 M
Decreased by -28.69%
Decreased by -1.39 K%
Increased by +54.45%
Dec 31, 21 367.00 K
Increased by +N/A%
-37.71 M
Decreased by -9.57%
Decreased by -10.28 K%
Decreased by N/A%
Sep 30, 21 1.54 M
Increased by +N/A%
-33.12 M
Increased by +0.52%
Decreased by -2.16 K%
Decreased by N/A%
Jun 30, 21 1.54 M
Increased by +N/A%
-29.82 M
Decreased by -43.38%
Decreased by -1.93 K%
Decreased by N/A%
Mar 31, 21 910.00 K
Increased by +N/A%
-27.67 M
Decreased by -38.17%
Decreased by -3.04 K%
Decreased by N/A%
Dec 31, 20 0.00
Decreased by N/A%
-34.42 M
Decreased by -89.29%
Decreased by N/A%
Decreased by N/A%
  • Top 20 ETF Stock Exposure
  • Top 20 Institutional Holders
  • Top 20 Mutual Fund Holders
Rank ETF Shares Market Value Weight % in ETF
Open dropdown content
Open dropdown content
DAILY
WEEKLY
MONTHLY

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB); and ALG-000184, a capsid assembly modulator, which is in Phase I clinical trials to treat CHB. The company also develops ALG-020572, an antisense oligonucleotide to prevent HBsAg translation and secretion; and ALG-055009, a small molecule THR-ß agonist that is in the Phase 1a/1b for the treatment of non-alcoholic steatohepatitis(NASH). In addition, it develops siRNA drug candidate, ALG-125755, as well as ALG-125097 and ALG-125819, demonstrated potent inhibition of HBsAg release from HBV-infected cells. It has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH. The company was incorporated in 2018 and is headquartered in South San Francisco, California.